Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4011499 + Cabotegravir in Treatment-Naïve HIV-1 (CINERGY)
NCT07816250Phase 2Not yet recruiting
- Sponsor
- ViiV Healthcare
- Start
- Oct 2026
- Primary completion
- Jun 2032
01
Overview
Phase 2, randomised, open-label trial of VH4011499 in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by ViiV Healthcare. Primary endpoint: Plasma HIV-1 RNA <50 copies/mL as per FDA snapshot algorithm at 7 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
VH4011499
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT07816250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07816250.